{"id":163805,"date":"2026-07-22T12:58:35","date_gmt":"2026-07-22T07:28:35","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=163805"},"modified":"2026-07-22T12:58:36","modified_gmt":"2026-07-22T07:28:36","slug":"pli-scheme-beneficiary-stocks-pharma-api-manufacturing-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/pli-scheme-beneficiary-stocks-pharma-api-manufacturing-2026\/","title":{"rendered":"3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Divi&#8217;s Laboratories, Laurus Labs and domestic API manufacturers continue benefiting from India&#8217;s production-linked incentive scheme for bulk drug manufacturing.<\/em><\/p>\n<p>Divi&#8217;s Laboratories, Laurus Labs and Aarti Drugs are among the PLI scheme beneficiary stocks in pharma and API manufacturing, each positioned within India&#8217;s PLI scheme pharma and API manufacturing beneficiaries growth story through distinct business drivers.<\/p>\n<p>India&#8217;s PLI scheme pharma and API manufacturing beneficiaries sector continues to see sustained investment and demand growth, and PLI scheme beneficiary stocks in pharma and API manufacturing reflects companies with the clearest exposure to this trend.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=pli-scheme-beneficiary-stocks-pharma-api-manufacturing\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<p>This article examines Divi&#8217;s Laboratories, Laurus Labs and Aarti Drugs as PLI scheme beneficiary stocks in pharma and API manufacturing, covering their specific growth drivers and the risks of this theme.<\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/pli-scheme-beneficiary-stocks-pharma-api-manufacturing-2026\/#What_Defines_the_3_PLI_Scheme_Beneficiary_Stocks_in_Pharma_and_API_Manufacturing\" title=\"What Defines the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing\">What Defines the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/pli-scheme-beneficiary-stocks-pharma-api-manufacturing-2026\/#Why_These_Are_the_3_PLI_Scheme_Beneficiary_Stocks_in_Pharma_and_API_Manufacturing\" title=\"Why These Are the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing\">Why These Are the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/pli-scheme-beneficiary-stocks-pharma-api-manufacturing-2026\/#Divis_Laboratories_Large-scale_api_manufacturer_benefiting_from_bulk_drug_pli_incentives\" title=\"Divi&#8217;s Laboratories: Large-scale api manufacturer benefiting from bulk drug pli incentives\">Divi&#8217;s Laboratories: Large-scale api manufacturer benefiting from bulk drug pli incentives<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/pli-scheme-beneficiary-stocks-pharma-api-manufacturing-2026\/#Laurus_Labs_Diversified_api_manufacturer_benefiting_from_bulk_drug_pli_scheme_incentives\" title=\"Laurus Labs: Diversified api manufacturer benefiting from bulk drug pli scheme incentives\">Laurus Labs: Diversified api manufacturer benefiting from bulk drug pli scheme incentives<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/pli-scheme-beneficiary-stocks-pharma-api-manufacturing-2026\/#Aarti_Drugs_Api_manufacturer_benefiting_from_bulk_drug_self-reliance_incentive_scheme\" title=\"Aarti Drugs: Api manufacturer benefiting from bulk drug self-reliance incentive scheme\">Aarti Drugs: Api manufacturer benefiting from bulk drug self-reliance incentive scheme<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/pli-scheme-beneficiary-stocks-pharma-api-manufacturing-2026\/#Factors_Affecting_the_3_PLI_Scheme_Beneficiary_Stocks_in_Pharma_and_API_Manufacturing\" title=\"Factors Affecting the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing\">Factors Affecting the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/pli-scheme-beneficiary-stocks-pharma-api-manufacturing-2026\/#Benefits_of_the_3_PLI_Scheme_Beneficiary_Stocks_in_Pharma_and_API_Manufacturing\" title=\"Benefits of the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing\">Benefits of the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/pli-scheme-beneficiary-stocks-pharma-api-manufacturing-2026\/#Risks_of_the_3_PLI_Scheme_Beneficiary_Stocks_in_Pharma_and_API_Manufacturing\" title=\"Risks of the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing\">Risks of the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/pli-scheme-beneficiary-stocks-pharma-api-manufacturing-2026\/#How_to_Evaluate_the_3_PLI_Scheme_Beneficiary_Stocks_in_Pharma_and_API_Manufacturing\" title=\"How to Evaluate the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing\">How to Evaluate the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/pli-scheme-beneficiary-stocks-pharma-api-manufacturing-2026\/#How_to_Invest_in_the_3_PLI_Scheme_Beneficiary_Stocks_in_Pharma_and_API_Manufacturing\" title=\"How to Invest in the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing\">How to Invest in the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/pli-scheme-beneficiary-stocks-pharma-api-manufacturing-2026\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/pli-scheme-beneficiary-stocks-pharma-api-manufacturing-2026\/#FAQs\" title=\"FAQs\">FAQs<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/pli-scheme-beneficiary-stocks-pharma-api-manufacturing-2026\/#3_PLI_Scheme_Beneficiary_Stocks_in_Pharma_and_API_Manufacturing\" title=\"3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing?\">3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/pli-scheme-beneficiary-stocks-pharma-api-manufacturing-2026\/#What_drives_Divis_Laboratoriess_growth_in_this_theme\" title=\"What drives Divi&#8217;s Laboratories&#8217;s growth in this theme?\">What drives Divi&#8217;s Laboratories&#8217;s growth in this theme?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/pli-scheme-beneficiary-stocks-pharma-api-manufacturing-2026\/#What_drives_Laurus_Labss_growth_in_this_theme\" title=\"What drives Laurus Labs&#8217;s growth in this theme?\">What drives Laurus Labs&#8217;s growth in this theme?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/pli-scheme-beneficiary-stocks-pharma-api-manufacturing-2026\/#What_drives_Aarti_Drugss_growth_in_this_theme\" title=\"What drives Aarti Drugs&#8217;s growth in this theme?\">What drives Aarti Drugs&#8217;s growth in this theme?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/pli-scheme-beneficiary-stocks-pharma-api-manufacturing-2026\/#Is_this_theme_purely_cyclical_or_structural\" title=\"Is this theme purely cyclical or structural?\">Is this theme purely cyclical or structural?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/pli-scheme-beneficiary-stocks-pharma-api-manufacturing-2026\/#What_risks_apply_to_the_3_PLI_Scheme_Beneficiary_Stocks_in_Pharma_and_API_Manufacturing\" title=\"What risks apply to the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing?\">What risks apply to the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Defines_the_3_PLI_Scheme_Beneficiary_Stocks_in_Pharma_and_API_Manufacturing\"><\/span><strong>What Defines the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The PLI scheme beneficiary stocks in pharma and API manufacturing are companies with direct exposure to PLI scheme pharma and API manufacturing beneficiaries, combining relevant scale with disclosed growth or expansion plans.<\/p>\n<p>Understanding these PLI scheme beneficiary stocks in pharma and API manufacturing helps investors identify names positioned to benefit from sustained sector-wide demand rather than one-off catalysts.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_These_Are_the_3_PLI_Scheme_Beneficiary_Stocks_in_Pharma_and_API_Manufacturing\"><\/span><strong>Why These Are the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Divi&#8217;s Laboratories&#8217;s large-scale API manufacturer benefiting from bulk drug PLI incentives, Laurus Labs&#8217;s diversified API manufacturer benefiting from bulk drug PLI scheme incentives and Aarti Drugs&#8217;s API manufacturer benefiting from bulk drug self-reliance incentive scheme together explain why these represent the PLI scheme beneficiary stocks in pharma and API manufacturing.<\/p>\n<ul>\n<li><strong>Divi&#8217;s Laboratories&#8217;s large-scale API manufacturer benefiting from bulk drug PLI incentives:<\/strong> Divi&#8217;s Laboratories&#8217;s its large-scale API and custom synthesis manufacturing, benefiting from PLI scheme incentives supporting domestic bulk drug production self-reliance.<\/li>\n<li><strong>Laurus Labs&#8217;s diversified API manufacturer benefiting from bulk drug PLI scheme incentives:<\/strong> Laurus Labs&#8217;s its diversified pharmaceutical manufacturing model, benefiting from PLI scheme incentives supporting domestic active pharmaceutical ingredient production.<\/li>\n<li><strong>Aarti Drugs&#8217;s API manufacturer benefiting from bulk drug self-reliance incentive scheme:<\/strong> Aarti Drugs&#8217;s its API manufacturing business, benefiting from India&#8217;s bulk drug self-reliance incentive scheme supporting reduced import dependence.<\/li>\n<li><strong>Sustained sector-wide demand:<\/strong> Broader structural demand growth across PLI scheme pharma and API manufacturing beneficiaries supports all three companies within this theme.<\/li>\n<\/ul>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"6\">\n<tbody>\n<tr>\n<th>Company<\/th>\n<th>CMP (Rs)<\/th>\n<th>Growth Driver<\/th>\n<th>Sector<\/th>\n<\/tr>\n<tr>\n<td>Divi&#8217;s Laboratories<\/td>\n<td>&#8211;<\/td>\n<td>Large-scale api manufacturer benefiting from bulk drug pli incentives<\/td>\n<td>Pli<\/td>\n<\/tr>\n<tr>\n<td>Laurus Labs<\/td>\n<td>&#8211;<\/td>\n<td>Diversified api manufacturer benefiting from bulk drug pli scheme incentives<\/td>\n<td>Pli<\/td>\n<\/tr>\n<tr>\n<td>Aarti Drugs<\/td>\n<td>&#8211;<\/td>\n<td>Api manufacturer benefiting from bulk drug self-reliance incentive scheme<\/td>\n<td>Pli<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"Divis_Laboratories_Large-scale_api_manufacturer_benefiting_from_bulk_drug_pli_incentives\"><\/span><strong>Divi&#8217;s Laboratories: Large-scale api manufacturer benefiting from bulk drug pli incentives<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Divi&#8217;s Laboratories is among the PLI scheme beneficiary stocks in pharma and API manufacturing, its large-scale API and custom synthesis manufacturing, benefiting from PLI scheme incentives supporting domestic bulk drug production self-reliance.<\/p>\n<p>Divi&#8217;s Laboratories&#8217; scale positions it to capture meaningful PLI-linked incentive benefits as India reduces API import dependence.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Laurus_Labs_Diversified_api_manufacturer_benefiting_from_bulk_drug_pli_scheme_incentives\"><\/span><strong>Laurus Labs: Diversified api manufacturer benefiting from bulk drug pli scheme incentives<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Laurus Labs is among the PLI scheme beneficiary stocks in pharma and API manufacturing, its diversified pharmaceutical manufacturing model, benefiting from PLI scheme incentives supporting domestic active pharmaceutical ingredient production.<\/p>\n<p>Laurus Labs&#8217; diversification across API, generics and CDMO services provides multiple avenues for capturing PLI-linked incentive benefits.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/sebi-registered-investment-advisor-india\"><strong>Get SEBI-Registered Research on PLI Pharma API Manufacturing Stocks<\/strong><\/a><\/p>\n<h3><span class=\"ez-toc-section\" id=\"Aarti_Drugs_Api_manufacturer_benefiting_from_bulk_drug_self-reliance_incentive_scheme\"><\/span><strong>Aarti Drugs: Api manufacturer benefiting from bulk drug self-reliance incentive scheme<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Aarti Drugs is among the PLI scheme beneficiary stocks in pharma and API manufacturing, its API manufacturing business, benefiting from India&#8217;s bulk drug self-reliance incentive scheme supporting reduced import dependence.<\/p>\n<p>Aarti Drugs&#8217; domestic API manufacturing focus positions it to capture incentive benefits tied to India&#8217;s pharmaceutical self-reliance policy.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Divi&#8217;s Laboratories, Laurus Labs and Aarti Drugs live prices.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Factors_Affecting_the_3_PLI_Scheme_Beneficiary_Stocks_in_Pharma_and_API_Manufacturing\"><\/span><strong>Factors Affecting the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Execution track record:<\/strong> For the PLI scheme beneficiary stocks in pharma and API manufacturing, execution against disclosed plans remains the key determinant of realised growth.<\/li>\n<li><strong>Sector-wide demand trends:<\/strong> Broader demand trends across PLI scheme pharma and API manufacturing beneficiaries affect all three companies collectively.<\/li>\n<li><strong>Competitive intensity:<\/strong> Rising competition within PLI scheme pharma and API manufacturing beneficiaries could pressure margins even amid volume growth.<\/li>\n<li><strong>Input cost and supply chain factors:<\/strong> Cost and supply chain dynamics affect profitability for companies within this theme.<\/li>\n<li><strong>Policy and regulatory support:<\/strong> Government policy support toward PLI scheme pharma and API manufacturing beneficiaries affects the sustainability of this growth theme.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Benefits_of_the_3_PLI_Scheme_Beneficiary_Stocks_in_Pharma_and_API_Manufacturing\"><\/span><strong>Benefits of the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Structural growth theme exposure:<\/strong> The PLI scheme beneficiary stocks in pharma and API manufacturing provide exposure to a sustained, structural growth theme rather than a short-term cycle.<\/li>\n<li><strong>Diversified company selection:<\/strong> Spanning three companies, this list reduces single-stock concentration risk within the theme.<\/li>\n<li><strong>Established execution capability:<\/strong> These companies bring existing scale and expertise to capture growth within PLI scheme pharma and API manufacturing beneficiaries.<\/li>\n<li><strong>Policy-aligned positioning:<\/strong> These stocks align with broader government policy priorities supporting this sector.<\/li>\n<li><strong>Multiple growth vectors:<\/strong> Different business models across these three names offer diversified ways to capture the same broad theme.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Risks_of_the_3_PLI_Scheme_Beneficiary_Stocks_in_Pharma_and_API_Manufacturing\"><\/span><strong>Risks of the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Execution risk:<\/strong> These companies still need to execute disclosed plans successfully to realise growth.<\/li>\n<li><strong>Valuation considerations:<\/strong> Strong recent sector performance means current valuations may already reflect growth expectations for the PLI scheme beneficiary stocks in pharma and API manufacturing.<\/li>\n<li><strong>Competitive pressure:<\/strong> Rising competition within PLI scheme pharma and API manufacturing beneficiaries could affect market share and margins over time.<\/li>\n<li><strong>Cyclicality risk:<\/strong> Demand within PLI scheme pharma and API manufacturing beneficiaries could prove more cyclical than currently anticipated.<\/li>\n<li><strong>Broader market sentiment risk:<\/strong> Overall market conditions can affect these stocks regardless of company-specific fundamentals.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Evaluate_the_3_PLI_Scheme_Beneficiary_Stocks_in_Pharma_and_API_Manufacturing\"><\/span><strong>How to Evaluate the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ol>\n<li>Among the PLI scheme beneficiary stocks in pharma and API manufacturing, compare execution track record against disclosed growth and expansion plans.<\/li>\n<li>For the PLI scheme beneficiary stocks in pharma and API manufacturing, assess competitive positioning within the broader PLI scheme pharma and API manufacturing beneficiaries sector.<\/li>\n<li>Track quarterly results to confirm continued execution progress.<\/li>\n<li>Consider valuation relative to growth visibility for each name.<\/li>\n<li>Combine sector-theme analysis with standard fundamental research.<\/li>\n<\/ol>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Invest_in_the_3_PLI_Scheme_Beneficiary_Stocks_in_Pharma_and_API_Manufacturing\"><\/span><strong>How to Invest in the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ol>\n<li>Use the Univest platform to track quarterly results and expansion progress for the PLI scheme beneficiary stocks in pharma and API manufacturing.<\/li>\n<li>Open a demat and trading account with Univest for zero-brokerage execution.<\/li>\n<li>Track quarterly results for Divi&#8217;s Laboratories, Laurus Labs and Aarti Drugs through the Univest app.<\/li>\n<li>Consult a SEBI-registered advisor before allocating capital to this theme.<\/li>\n<li>Review positions periodically as execution progress and sector trends evolve.<\/li>\n<\/ol>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Divi&#8217;s Laboratories, Laurus Labs and Aarti Drugs represent the PLI scheme beneficiary stocks in pharma and API manufacturing, each capturing different aspects of India&#8217;s sustained PLI scheme pharma and API manufacturing beneficiaries growth story. Historically, this structural theme has offered diversified exposure across multiple companies, though execution risk and valuation considerations remain important factors. Consult a SEBI-registered advisor before making investment decisions.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"3_PLI_Scheme_Beneficiary_Stocks_in_Pharma_and_API_Manufacturing\"><\/span><strong>3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Divi&#8217;s Laboratories, Laurus Labs and Aarti Drugs are the PLI scheme beneficiary stocks in pharma and API manufacturing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_drives_Divis_Laboratoriess_growth_in_this_theme\"><\/span><strong>What drives Divi&#8217;s Laboratories&#8217;s growth in this theme?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Divi&#8217;s Laboratories benefits from large-scale API manufacturer benefiting from bulk drug PLI incentives.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_drives_Laurus_Labss_growth_in_this_theme\"><\/span><strong>What drives Laurus Labs&#8217;s growth in this theme?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Laurus Labs benefits from diversified API manufacturer benefiting from bulk drug PLI scheme incentives.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_drives_Aarti_Drugss_growth_in_this_theme\"><\/span><strong>What drives Aarti Drugs&#8217;s growth in this theme?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Aarti Drugs benefits from API manufacturer benefiting from bulk drug self-reliance incentive scheme.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_theme_purely_cyclical_or_structural\"><\/span><strong>Is this theme purely cyclical or structural?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The PLI scheme beneficiary stocks in pharma and API manufacturing represent a structural growth theme, though cyclicality risk remains a consideration.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_apply_to_the_3_PLI_Scheme_Beneficiary_Stocks_in_Pharma_and_API_Manufacturing\"><\/span><strong>What risks apply to the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Key risks include execution risk, valuation considerations, and competitive pressure within the sector.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Divi's Laboratories, Laurus Labs and Aarti Drugs are the PLI scheme beneficiary stocks in pharma and API manufacturing.\"}},{\"@type\":\"Question\",\"name\":\"What drives Divi's Laboratories's growth in this theme?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Divi's Laboratories benefits from large-scale API manufacturer benefiting from bulk drug PLI incentives.\"}},{\"@type\":\"Question\",\"name\":\"What drives Laurus Labs's growth in this theme?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Laurus Labs benefits from diversified API manufacturer benefiting from bulk drug PLI scheme incentives.\"}},{\"@type\":\"Question\",\"name\":\"What drives Aarti Drugs's growth in this theme?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Aarti Drugs benefits from API manufacturer benefiting from bulk drug self-reliance incentive scheme.\"}},{\"@type\":\"Question\",\"name\":\"Is this theme purely cyclical or structural?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The PLI scheme beneficiary stocks in pharma and API manufacturing represent a structural growth theme, though cyclicality risk remains a consideration.\"}},{\"@type\":\"Question\",\"name\":\"What risks apply to the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Key risks include execution risk, valuation considerations, and competitive pressure within the sector.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>3 PLI scheme beneficiary stocks in pharma and API manufacturing, Aarti Drugs, Divi&#8217;s Laboratories and Laurus Labs, capture India&#8217;s bulk drug self-reliance push.<\/p>\n","protected":false},"author":35,"featured_media":163803,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-163805","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["163803"],"_edit_lock":["1784705324:29"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["74"],"rank_math_title":["3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing"],"rank_math_description":["3 PLI scheme beneficiary stocks in pharma and API manufacturing, Aarti Drugs, Divi's Laboratories and Laurus Labs, capture India's bulk drug self-reliance push."],"rank_math_focus_keyword":["PLI scheme beneficiary stocks in pharma and API manufacturing"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_edit_last":["29"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["29238"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/07\/pli-scheme-beneficiary-stocks-pharma-api-manufacturing-2026.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/163805","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=163805"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/163805\/revisions"}],"predecessor-version":[{"id":163824,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/163805\/revisions\/163824"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/163803"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=163805"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=163805"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=163805"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}